Orphan drug designation applies to patients with primary mitochondrial myopathy due to nuclear DNA mutations (nPMM) in the NuPower Phase 3 clinical trial
NuPOWER Phase 3 trial is currently enrolling patients with multiple clinical trial sites initiated in the United States and Europe
https://finance.yahoo.com/news/stealth-biotherapeutics-receives-orphan-drug-112500829.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.